In a seed round led by Antler & with participation from Venture Catalysts, Hatcher+, and We Founder Circle, Biotech Startup Cellivate Technologies has lifted $1 million.

According to a press release from Cellivate, the funds will be used to accelerate its R&D efforts, scale up production of its innovative products, and broaden its market reach.

Founded by Viknish Krishnan Kutty, Cellivate is creating inventive solutions for address critical difficulties in cell culture and bio-manufacturing.

Advanced micro-carriers for accelerating cell growth and a novel cell-based serum that can take the place of fetal bovine serum are among the company's most popular offerings.

Market research indicates that the cell culture market, particularly for serum and microcarriers, will reach $33 billion by 2030.

Cellivate says that its high level microcarriers and cell-based serum options can possibly decrease costs, increase proficiency, and address ethical worries in cell culture processes. Since a number of products and ingredients that are typically derived from animals can be obtained from cells, advancements in cell culture and bio-manufacturing-related technologies will lessen society’s reliance on the slaughter of animals.

They develop & commercialize the proprietary products & technologies which resolve the hold ups tackled by cell-based firms at diverse stages of the value chain. Their solutions permit them to hasten and strengthen the overall processes at minimal costs and are adaptable to various applications of cell culture. Upon this, they have early adhesion in the cosmetics, cultivated meat and leather fields.